June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses. Upfront Payment $7.0MM Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study Milestone 2.0 $88.5MM […]